Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics PLC (AUTL) is a clinical-stage biopharmaceutical leader pioneering engineered T-cell therapies for cancer treatment. This page serves as the definitive source for verified news and official updates on the company’s immunotherapy advancements, clinical trial progress, and strategic initiatives.
Investors and researchers will find timely updates on key developments including regulatory milestones, partnership announcements, and pipeline advancements. Our curated collection ensures access to primary-source information spanning clinical data releases, financial reports, and scientific presentations – all critical for informed analysis of AUTL’s position in the competitive oncology biotech sector.
Content highlights include updates on lead candidates like Obe-cel, technology platform innovations, and collaborations advancing next-generation cellular therapies. Each release is vetted for relevance to investment research and therapeutic development tracking.
Bookmark this page for streamlined monitoring of Autolus’ progress in developing precision T-cell treatments for hematological malignancies and solid tumors. Check regularly for authoritative updates directly impacting the evaluation of AUTL’s scientific and market potential.
Autolus (NASDAQ: AUTL) presented updated Phase 1 CARLYSLE data for obe-cel in severe refractory systemic lupus erythematosus (srSLE) at ASH on Dec 8, 2025.
Nine adults were infused (six at 50×10^6 cells, three at 100×10^6). At 50M, CRR 50% (3/6) and DORIS 83% (5/6) were reported with median DORIS onset 5.1 months and median follow-up 12 months. All patients showed deep B-cell depletion; median CAR T-cell persistence was 3.0 months and peak expansion at a median of 10 days. Safety: no DLTs at 50M, no ICANS, Grade 1 CRS in three patients at 50M and three at 100M; one transient Grade 3 liver toxicity in 100M cohort; hypertension observed in five patients at 50M.
50M chosen as recommended Phase 2 dose; LUMINA Phase 2 in lupus nephritis with registrational intent is now enrolling and aligned with FDA.
Autolus (NASDAQ: AUTL) presented clinical and real-world data on obecabtagene autoleucel (obe-cel) at ASH 2025 showing high remission rates and a favorable safety profile. In pediatric CATULUS data (n=21) the overall response rate was 95.5% with 90.9% CR, and high‑grade CRS and ICANS each occurred in 8.7% of patients; median follow-up was 8.8 months. FELIX post-hoc analyses found CAR T persistence at Month 3 (75.9%) associated with longer EFS and OS. Product cell phenotype (higher Tcm %) correlated with better outcomes. Real-world ROCCA data during the US launch mirrored low rates of high‑grade CRS and ICANS.
Autolus Therapeutics (Nasdaq: AUTL) announced the appointment of Ryan Richardson to its Board of Directors effective Dec 1, 2025.
Mr. Richardson brings more than 20 years of strategy and corporate development experience, including service as Chief Strategy Officer and management board member at BioNTech from Sept 2018 to Sept 2025. The company said his background in corporate development, capital markets, IPOs, financings and M&A will support Autolus' transition as a commercial-stage company and advance commercial launch and expansion efforts for obe-cel.
His prior roles include Executive Director at J.P. Morgan Global Healthcare Investment Banking (2011–2018) and chairmanship at Instadeep following BioNTech's 2023 acquisition.
Autolus Therapeutics (Nasdaq: AUTL) announced that NICE published draft guidance recommending AUCATZYL® (obecabtagene autoleucel) as a treatment option for adult patients aged ≥26 years with relapsed or refractory B‑cell precursor acute lymphoblastic leukemia (r/r B‑ALL).
AUCATZYL will be available through routine commissioning by the NHS in England and Wales and Autolus intends to launch imminently while pursuing Scottish access. The MHRA granted conditional marketing authorisation in April 2025, based on the FELIX study published in the New England Journal of Medicine in November 2024.
Autolus Therapeutics (Nasdaq: AUTL) will participate in the Jefferies Global Healthcare Conference in London. CEO Dr. Christian Itin will appear in a fireside chat on Tuesday, November 18, 2025 at 7:30 AM EST / 12:30 PM GMT. A live webcast will be available on the company’s Events page and a replay will be archived on the website for 90 days after the presentation.
The presentation covers company updates and investor engagement; webcast access is via the company investor relations site.
Autolus Therapeutics (Nasdaq: AUTL) reported Q3 2025 results and operational updates on Nov 12, 2025. Key commercial metrics: Q3 net product revenue $21.1M, deferred revenue $7.6M, and 60 U.S. treatment centers activated as of Nov 12, 2025. Cash and marketable securities totaled $367.4M at Sept 30, 2025.
Clinical highlights include rmAT designation for obe-cel in pediatric r/r B-ALL, CARLYSLE Phase 1 data in severe refractory SLE showing DORIS remission in 83% (5/6) and CRR in 50% (3/6), and first patient dosed in a progressive MS Phase 1 trial. Management additions announced to support commercialization and manufacturing.
Autolus (Nasdaq: AUTL) announced five abstracts for presentation at the ASH Annual Meeting (Dec 6-9, 2025) detailing clinical updates for obe-cel (obecabtagene autoleucel) across autoimmune and hematologic indications.
Key points: Phase I CARLYSLE data in severe refractory SLE show pronounced CAR T expansion, deep B-cell depletion and clinical benefit; pediatric CATULUS trial reports ORR 95% and ~90% ongoing remissions at cutoff; drug-product phenotypes (higher Tcm) correlated with improved OS; Month 3 CAR T persistence predicts longer EFS/OS; commercially available reagents can track obe-cel but CD19-based reagents are unsuitable.
Autolus Therapeutics (Nasdaq: AUTL) will release its third quarter 2025 financial results and operational highlights before U.S. market open on Wednesday, November 12, 2025. Management will host a conference call and webcast at 8:30 AM EST / 1:30 PM GMT to discuss results and provide a business update. Participants must pre-register to receive dial-in numbers and a personal PIN required for access. A simultaneous audio webcast and a replay will be available from the events section of Autolus’ investor website.
Autolus Therapeutics (NASDAQ: AUTL)50x10^6 cells (±20%) with median follow-up of 8.9 months (range 6.0–13.8).
Key findings: no DLTs, no ICANS, no Grade ≥2 CRS; remission by DORIS in 83.3% (5/6); complete renal response in 50% (3/6); all patients tapered steroids to ≤5 mg/day; deep B-cell depletion followed by naïve B-cell reconstitution. Company expects to dose first Phase 2 LN patient before year-end 2025 and reports alignment with the FDA on trial design.
Autolus Therapeutics (Nasdaq: AUTL) announced dosing of the first patient in the Phase 1 BOBCAT trial of obecabtagene autoleucel (obe-cel) for progressive multiple sclerosis (PMS) on Oct 20, 2025. The trial, led at University College London Hospitals, will enroll up to 18 adults with refractory progressive MS to evaluate safety, tolerability and collect preliminary efficacy and biological-effect data using change-from-baseline standard measures. Autolus highlights obe-cel’s fast-off rate CAR design and notes the therapy has been studied in more than 400 patients to date and is approved in certain regions for adult relapsed/refractory B-ALL.
This dosing marks an early clinical milestone as the company explores a one-time CAR T approach for an unmet need in PMS.
FAQ
What is the current stock price of AUTOLUS THERAPEUTICS PLC (AUTL)?
What is the market cap of AUTOLUS THERAPEUTICS PLC (AUTL)?
